Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention

References

• Goto S, Bhatt DL, Rother J, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J. 2008 Nov;156(5):855–863.e2.
   PubMed Web of Science ®Google Scholar
• Depta JP, Cannon CP, Fonarow GC, et al. Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes. Am J Cardiol. 2009 Nov 1;104(9):1171–1178.
   PubMed Web of Science ®Google Scholar
• Depta JP, Bhatt DL. Atherothrombosis and atrial fibrillation: important and often overlapping clinical syndromes. Thromb Haemost. 2010 Oct;104(4):657–663.
   PubMed Web of Science ®Google Scholar
• Kralev S, Schneider K, Lang S, et al. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. Plos One. 2011;6(9):e24964.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events–european registry in atrial fibrillation (PREFER in AF). Europace. 2014 Jan;16(1):6–14.
   PubMed Web of Science ®Google Scholar
• Lip GY, Laroche C, Dan GA, et al. A prospective survey in european society of cardiology member countries of atrial fibrillation management: baseline results of EURObservational research programme atrial fibrillation (EORP-AF) pilot general registry. Europace. 2014 Mar;16(3):308–319.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Bhatt DL, Steg PG, et al. Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. Int J Cardiol. 2014 Jan 1;170(3):413–418.
   PubMed Web of Science ®Google Scholar
• Bang CN, Gislason GH, Greve AM, et al. New-onset atrial fibrillation is associated with cardiovascular events leading to death in a first time myocardial infarction population of 89,703 patients with long-term follow-up: a nationwide study. J Am Heart Assoc. 2014 Jan 21;3(1):e000382.
   PubMed Web of Science ®Google Scholar
• Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996 Apr 25;334(17):1084–1089.
   PubMed Web of Science ®Google Scholar
• Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent anticoagulation restenosis study investigators. N Engl J Med. 1998Dec 3;339(23):1665–1671.
   PubMed Web of Science ®Google Scholar
• De Luca G, Dirksen MT, Spaulding C, et al. Time course, predictors and clinical implications of stent thrombosis following primary angioplasty. Insights from the DESERT cooperation. Thromb Haemost. 2013 Oct;110(4):826–833.
   PubMed Web of Science ®Google Scholar
• ACTIVE Writing Group of the ACTIVE Investigators. Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. Lancet. 2006 Jun 10;367(9526):1903–1912.
   PubMed Web of Science ®Google Scholar
• Pastori D, Pignatelli P, Angelico F, et al. Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors. Chest. 2015 Jun;147(6):1644–1650.
   PubMed Web of Science ®Google Scholar
• Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736–2747.
   PubMed Web of Science ®Google Scholar
• Sorensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009 Dec 12;374(9706):1967–1974.
   PubMed Web of Science ®Google Scholar
• Grove EL, Storey RF. The right oral antithrombotics in acute coronary syndromes. Lancet. 2009 Dec 12;374(9706):1947–1948.
   PubMed Web of Science ®Google Scholar
• Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010 Sep 13;170(16):1433–1441.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Mehta SR, Anand SS, et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006 Aug 22;114(8):774–782.
   PubMed Web of Science ®Google Scholar
• Bhatt DL. O PIONEERs! The beginning of the end of full-dose triple therapy with warfarin? Circulation. 2017 Jan 24;135(4):334–337.
   PubMed Web of Science ®Google Scholar
• Bhatt DL. Intensifying platelet inhibition–navigating between Scylla and Charybdis. N Engl J Med. 2007 Nov 15;357(20):2078–2081.
   PubMed Web of Science ®Google Scholar
• D’Ascenzo F, Taha S, Moretti C, et al. Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2015 May 1;115(9):1185–1193.
   PubMed Web of Science ®Google Scholar
• Gao XF, Chen Y, Fan ZG, et al. Antithrombotic regimens for patients taking oral anticoagulation after coronary intervention: a meta-analysis of 16 clinical trials and 9,185 patients. Clin Cardiol. 2015 Aug;38(8):499–509.
   PubMed Web of Science ®Google Scholar
• Bavishi C, Koulova A, Bangalore S, et al. Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation: A meta-analysis of observational studies. Catheter Cardiovasc Interv. 2016 Jul;88(1):E12–22.
   PubMed Web of Science ®Google Scholar
• Barbieri L, Verdoia M, Schaffer A, et al. Risk and benefits of triple therapy in patients undergoing coronary stent implantation requiring oral anticoagulation: a meta-analysis of 16 studies. Cardiovasc Drugs Ther. 2016 Dec;30(6):611–622.
   PubMed Web of Science ®Google Scholar
• Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012 Sep 4;126(10):1185–1193.
   PubMed Web of Science ®Google Scholar
• Lamberts M, Gislason GH, Olesen JB, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol. 2013 Sep 10;62(11):981–989.
   PubMed Web of Science ®Google Scholar
• Hess CN, Peterson ED, Peng SA, et al. Use and outcomes of triple therapy among older patients with acute myocardial infarction and atrial fibrillation. J Am Coll Cardiol. 2015 Aug 11;66(6):616–627.
   PubMed Web of Science ®Google Scholar
• Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013 Mar 30;381(9872):1107–1115.
   PubMed Web of Science ®Google Scholar
• Fiedler KA, Maeng M, Mehilli J, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol. 2015 Apr 28;65(16):1619–1629.
   PubMed Web of Science ®Google Scholar
• Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016 Dec 22;375(25):2423–2434.
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim. Evaluation of dual therapy with dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI). Available at: https://clinicaltrials.gov/ct2/show/NCT02164864. Accessed Feb 2, 2017.
   Google Scholar
• Cannon CP, Gropper S, Bhatt DL, et al. Design and rationale of the RE-DUAL PCI trial: a prospective, randomized, phase 3b study comparing the safety and efficacy of dual antithrombotic therapy with dabigatran etexilate versus warfarin triple therapy in patients with nonvalvular atrial fibrillation who have undergone percutaneous coronary intervention with stenting. Clin Cardiol. 2016 Oct;39(10):555–564.
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb, Pfizer. A study of apixaban in patients with atrial fibrillation, not caused by a heart valve problem, who are at risk for thrombosis (blood clots) due to having had a recent coronary event, such as a heart attack or a procedure to open the vessels of the heart. Available at: https://clinicaltrials.gov/ct2/show/NCT02415400. Accessed Feb 2, 2017.
   Google Scholar
• Daiichi Sankyo Inc. Edoxaban treatment versus vitamin k antagonist in patients with atrial fibrillation undergoing percutaneous coronary intervention (ENTRUST-AF-PCI). Available at: https://clinicaltrials.gov/ct2/show/NCT02866175. Accessed Feb 2, 2017.
   Google Scholar
• Bhatt DL. When is a double better than a TRIPLE?: stenting in patients with atrial fibrillation. J Am Coll Cardiol. 2015 Apr 28;65(16):1630–1632.
   PubMed Web of Science ®Google Scholar
• Gibson CM, Pinto DS, Chi G, et al. Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of rivaroxaban or a dose-adjusted oral vitamin k antagonist treatment strategy. Circulation. 2017 Jan 24;135(4):323–333.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883–891.
   PubMed Web of Science ®Google Scholar
• Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study. Circ J. 2012;76(9):2104–2111.
   PubMed Web of Science ®Google Scholar
• Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-Elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014 Dec 23;64(24):e139–228.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Dec 2;64(21):e1–76.
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Bittl JA, et al. ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;2016(Mar):23.
   Google Scholar
• Rubboli A, Faxon DP, Juhani Airaksinen KE, et al. The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. The 10th Anniversary Overview. Thromb Haemost. 2014 Dec;112(6):1080–1087.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Goodman SG, Bhatt DL, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a North American perspective-2016 update. Circ Cardiovasc Interv. 2016;9(11:e004395.
   Web of Science ®Google Scholar
• Lip GY, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014 Dec 1;35(45):3155–3179.
   PubMed Web of Science ®Google Scholar
• Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016 Jan 14;37(3):267–315.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 Oct 7;37(38):2893–2962.
   PubMed Web of Science ®Google Scholar
• Steg PG, Bhatt DL. Viewpoint: a proposal for a simple algorithm for managing oral anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation and coronary stents. Eur Heart J Acute Cardiovasc Care. 2017;6(1):93–97.
   Web of Science ®Google Scholar
• Bavishi C, Panwar SR, Dangas GD, et al. Meta-analysis of radial versus femoral access for percutaneous coronary interventions in Non-ST-Segment elevation acute coronary syndrome. Am J Cardiol. 2016 Jan 15;117(2):172–178.
   PubMed Web of Science ®Google Scholar
• Urban P, Meredith IT, Abizaid A, et al. Polymer-free Drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015 Nov 19;373(21):2038–2047.
   PubMed Web of Science ®Google Scholar
• Rossini R, Musumeci G, Lettieri C, et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am J Cardiol. 2008 Dec 15;102(12):1618–1623.
   PubMed Web of Science ®Google Scholar
• Grove EL, Wurtz M, Thomas MR, et al. Antiplatelet therapy in acute coronary syndromes. Expert Opin Pharmacother. 2015;16(14):2133–2147.
   PubMed Web of Science ®Google Scholar
• Agewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. 2013 Jun;34(23):1708-13, 1713a-1713b.
   Web of Science ®Google Scholar
• Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A report of the American college of cardiology foundation task force on expert consensus documents. J Am Coll Cardiol. 2010 Dec 7;56(24):2051–2066.
   PubMed Web of Science ®Google Scholar
• Kim YH, Lee JY, Ahn JM, et al. Impact of bleeding on subsequent early and late mortality after drug-eluting stent implantation. JACC Cardiovasc Interv. 2011 Apr;4(4):423–431.
   PubMed Web of Science ®Google Scholar
• CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet. 1996 Nov 16;348(9038):1329–1339.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Hirsch AT, Ringleb PA, et al. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. Am Heart J. 2000 Jul;140(1):67–73.
   PubMed Web of Science ®Google Scholar
• Ohman EM, Roe MT, Steg PG, et al. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet. 2017;389(10081):1799–1808.
   PubMed Web of Science ®Google Scholar
• ECRI bv, Biosensors International, AstraZeneca, The Medicines Company. GLOBAL LEADERS: a clinical study comparing two forms of anti-platelet therapy after stent implantation. Available at: https://clinicaltrials.gov/ct2/show/NCT01813435. Accessed Apr 2, 2017.
   Google Scholar
• Icahn School of Medicine at Mount Sinai, AstraZeneca. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention (TWILIGHT). Available at: https://clinicaltrials.gov/ct2/show/NCT02270242. Accessed Apr 2, 2017.
   Google Scholar
• Pignatelli P, Pastori D, Bartimoccia S, et al. Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding. Pharmacol Res. 2016 Nov;113(Pt A):484–489.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139–1151.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369(22):2093–2104.
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb. Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation (RENAL-AF). Available at: https://clinicaltrials.gov/ct2/show/NCT02942407. Accessed Apr 29, 2017.
   Google Scholar
• McCarthy CP, Verma S, Bhatt DL. The management of antiplatelet and antithrombotic regimens in patients with mechanical valves undergoing percutaneous coronary intervention: a forgotten cohort? JAMA Cardiol. 2017 Apr 26. doi:10.1001/jamacardio.2017.0930. [Epub ahead of print]
   Google Scholar